A Europe-based private equity firm founded in 2009 has a fund focused solely on oncology. The firm aims to fill the gap between equity and acquisition, and would be the first to get involved in assets that are seeking to spin-out of universities or research institutes. The firm typically acquires stakes and identifies ways to aggregate oncology technologies. The firm’s investment size ranges from $10M-$25M dependent on the company and product. The firm typically seeks co-investors to participate in a round. The firm has predominantly invested in companies based in the UK, though is open to investments on a global level, and is particularly seeking new opportunities in the US.

The firm invests in all sectors and subsectors of technology in oncology – therapeutics, 510K and PMA medical devices, diagnostics, and healthcare IT, along with oncology technology in palliative care. The firm is particularly loyal to its portfolio companies, as it typically makes investments in early-stage post proof-of-concept companies, and remains in the investment until commercialization.

The firm will help fill the management team, and may actively manage; takeover the management; participate in the advisory board; and/or advise the company after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital founded in 1992 and based in Virginia invests in life science companies primarily in the growth stage or at the series A or B round; if investing early, the firm would be part of a syndicate. The firm typically invests around $1-$15M into early companies, and $10M-$30M into growth stage companies. The firm seeks to make 10-15 new investments within the next year. While the firm focuses on companies based in USA and Canada due to practical matters, they may be open to investments on a global level.

The firm has a primary focus in healthcare IT, particularly in EMR companies, analytics, and any next generation IT tools for enterprise or ambulatory settings. The firm’s secondary focus is in tools and diagnostics, specifically in 510K genomics diagnostics, though is open to any kind of new diagnostic tool or test. The firm currently does not have interest in therapeutics or medical technology. The firm prefers companies with a commercialized product that is producing revenue, though does not have a revenue requirement and may be open to clinical stage products. 

The firm focuses on growth stage companies where 80% of their invested companies have revenue with a product looking to expand in the market and 20% of invested companies at the pre-revenue, close to commercialization stage. The firm typically invests in pre-revenue companies when the technology is close to commercialization (i.e. steps away from approval) and/or when the company has a strong management team with members the firm has known from before.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm located in the US Southeast has $1 billion in assets under management. The firm is interested in companies located all over the globe and makes 1-3 equity investments per year into commercial stage, revenue generating companies. The firm will lead a round if it is less than $20m but – if larger, co-invests alongside other private equity firms that it has relationships with. The minimum investment size is $1 million.

The firm is interested in therapeutics, medical devices, R&D services, and suppliers & engineering. The firm is particularly interested in over-the-counter and consumer health products and is otherwise open to all indication areas. Within medtech, the firm looks for products that have already received regulatory approval. Within therapeutics, the firm will consider Phase 3 or later. Orphan diseases are of interest as well.

The firm has no fixed management team requirements and takes a board seat on all investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A large pharma company based in Hong Kong makes equity investments and also in-licenses assets for development. Typical equity investments range from $2-3M per deal. The firm has partnered with companies in Japan, the USA and Europe, and is currently looking for new opportunities globally.

Currently the firm is seeking therapeutics in oncology, supportive care, cardiovascular, and ophthalmology. The firm focuses on small molecule, biologics, biosimilars, and repurposed and reformulated drugs. The firm typically in-licenses assets that have completed IND enabling studies, while it can consider from pre-clinical to on-market assets.

The firm is seeking innovative assets that address large unmet medical need. The firm generally seeks development and/or commercialization rights in China and Southeast Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A firm based in Switzerland is a specialized investor in oncology, and is currently investing from a fund of USD 51 million. The firm generally makes investments in Series A, B or C equity rounds; the firm is not interested in seed rounds. The firm typically makes allocations of $3-8 million, and may either lead investments or act as a co-investor alongside a syndicate. The firm is open to oncology opportunities globally but has recently invested primarily in the USA.

The firm is currently focused on oncology therapeutics. The firm will consider any form of therapeutic molecule in oncology, including small molecules, antibodies or new technologies such as cell therapies. The firm generally invests at the late preclinical stage, from 6-12 months pre-IND, but is also interested in companies Phase I or Phase II assets.

The firm places high importance on the management team’s scientific rigor and industry experience; the firm prefers to work with entrepreneurs who have led biotech companies previously. The firm also considers the strength of the investor syndicate and their alignment of interests.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm with offices worldwide specialises in early stage investments in the technology and life sciences sectors. The firm accelerates commercialisation of ground-breaking innovation through investments, experienced hands-on management and the intelligent use of partnering. The firm typically invest at seed stage or before a company has been formed and develop these early opportunities through preclinical phase; at late preclinical/early clinical stage the firm gets co-investors involved. The firm prefers areas where there are multiple capital efficient routes to market, with opportunities for early proof of concept or early outlicensing or exits. The firm manages a $150M fund and makes investments from $100K to $10M, depending on the opportunity. The firm is seeking a couple of opportunities to add to its portfolio. The firm invests in companies based in the USA and/or Europe.

The firm looks at early stage biotech therapeutics. In terms of indications, the firm is interested in anti-infectives and particularly antimicrobial resistance, as well as immuno-modulatory anti-inflammatory indications and orphan and rare diseases.

The firm looks for a strong management team with track record and a ground-breaking technology addressing an unmet need. The firm seeks to take significant minority stakes and board seats. In addition, the firm will provide hands-on support from its own bench of senior execs, experts and advisors to accelerate its ventures after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm that was founded in 2008 and is based in California makes equity allocations between $5-$50m in medical devices and advanced biotechnologies such as synthetic biology. The firm is currently seeking opportunities globally.

The firm manages a bioventures fund that investment strategies in/around advanced biotechnologies. This focus includes scalable, portable and sustainable technologies within high human-imperative sectors such as agriculture-food, energy-resources, industrial chemicals-materials, water-environment, and defense-space. The firm also has an interest in medical devices of any size, stage, geographic location and indication area. The firm is stage-agnostic and considers from seed and venture stage products to on-market products.

The firm is seeking experienced management teams. The firm typically takes a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com